Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.
Actively Recruiting
Researchers are evaluating the effects of zigakibart on the progression of Immunoglobulin A Nephropathy IgAN, a kidney disease. This open-label, multicenter study involves adult participants with IgAN who are randomized into two groups differing only by the timing of an on-treatment kidney biopsy, either at the end of the first or second year of treatment. The study is sponsored by Novartis Pharmaceuticals and aims to assess kidney disease markers and dysfunction over time. Participants receive zigakibart as 600 mg subcutaneous injections every two weeks for up to two years 104 weeks. The total participation period may last up to 125 weeks, including an 8-week screening, the 104-week treatment period, and a 13-week safety follow-up. The study measures changes in kidney tissue IgA deposits, protein levels in urine, kidney function, and immune markers among others. Throughout the study, participants will undergo regular evaluations including kidney biopsies, blood and urine tests, and monitoring of side effects. Researchers will track changes in various disease and immune markers at multiple time points during and after treatment. Safety is closely monitored during the 13-week follow-up after treatment ends. The total commitment for participants can last nearly two and a half years.
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Researchers are evaluating the effects of felzartamab in adults with Immunoglobulin A nephropathy IgAN, a kidney disease caused by the buildup of abnormal IgA antibodies in the kidneys. This buildup leads to inflammation and damage, resulting in protein in the urine proteinuria. The study aims to learn how felzartamab affects proteinuria and kidney function compared to a placebo, while also assessing the safety and how the drug is processed by the body. Participants will be randomly assigned to receive either intravenous IV infusions of felzartamab or a placebo that contains no active medicine. The treatment period lasts for 24 weeks, followed by an 80-week follow-up period. Some participants with lower kidney filtration rates will be included in specific cohorts receiving either felzartamab or placebo. Overall, participants will have 17 study visits during about 2 years in the trial. During the study, participants will undergo various assessments including urine protein measurement, kidney function tests using estimated glomerular filtration rate eGFR, and monitoring for immune responses and adverse events. Blood samples will be collected to measure drug levels and antibodies against felzartamab. Safety will be monitored through vital signs, laboratory tests, physical exams, and ECGs. Researchers will evaluate changes from baseline up to 36 weeks for proteinuria and up to 104 weeks for kidney function and safety outcomes.
Actively Recruiting
Researchers are tracking the course of primary membranous nephropathy PMN, a rare autoimmune kidney disease that causes nephrotic syndrome in adults. The study focuses on understanding long-term outcomes for patients in real-world clinical practice, especially in light of new treatment options such as monoclonal antibodies. The goal is to gain insights into disease progression and response to these therapies over time. Participants will be observed without any experimental treatment assigned by the study. The focus is on patients diagnosed with PMN and nephrotic syndrome who have been treated with rituximab or other monoclonal antibodies as part of their care. Researchers will collect data from routine clinical visits and follow patients longitudinally to capture disease remission, progression, and treatment effects. During the study, participants will provide consent for their medical data to be used for research. Researchers will monitor disease remission and progression, kidney function decline, blood parameters, and any adverse events related to treatment throughout the study, which typically spans about six months on average. The study will help understand outcomes and predictors in patients managed with current therapies and support better future care.
Actively Recruiting
Researchers are studying idiopathic nephrotic syndrome INS, which includes minimal change disease MCD and focal segmental glomerulosclerosis FSGS, and comparing it to primary membranous nephropathy MN. The goal is to evaluate the levels of circulating anti-nephrin autoantibodies, which may play a role in INS and post-transplant FSGS relapse. INS is a serious kidney condition with unclear causes and limited treatment options, especially when it recurs after transplantation. The study involves testing stored blood samples from patients with biopsy-confirmed idiopathic MCD or FSGS and those with membranous nephropathy. These samples will be analyzed using specialized ELISA tests to measure anti-nephrin autoantibody levels. The tests use recombinant nephrin protein and antibodies to detect these autoantibodies in the blood, comparing patients with INS to those with MN. Participants have previously provided consent for their samples to be stored in a certified biobank. Researchers will analyze these samples retrospectively over about one year to measure antibody levels. The study focuses on laboratory analysis without direct patient involvement, aiming to better understand the potential role of anti-nephrin autoantibodies in nephrotic syndrome and its recurrence after kidney transplant.
Actively Recruiting
Healthy Volunteer
Researchers are investigating membranous nephropathy MN, a common cause of nephrotic syndrome in adults, focusing on the role of autoreactive B cells that produce antibodies against the PLA2R receptor. The study aims to understand why some patients respond to B-cell depleting treatments while others do not, by comparing circulating immune cells in responders, non-responders, and healthy controls. This observational study will help identify differences in immune cell behavior related to treatment outcomes. The study includes patients with biopsy-confirmed idiopathic MN who are either planned to receive or have already received B-cell depleting therapy, as well as healthy volunteers without significant illnesses. Researchers will analyze blood samples using biochemical and flow cytometry assays to measure the frequency and activity of various B-cell subsets and other immune cells over a 24-month period. This includes assessments at baseline and multiple follow-up points at 3, 6, 9, 12, and 24 months. Participants will provide blood specimens that will be tested to evaluate the presence and function of autoreactive B cells and other immune cell types. The study will track changes in these immune cells over time, correlating findings with treatment response. The research involves no interventional treatments but focuses on extensive immune monitoring to better understand MN disease mechanisms and predict outcomes. Participation duration varies, with multiple follow-up visits for sample collection and immune profiling.
Actively Recruiting
Healthy Volunteer
Researchers are exploring how RNA sequencing RNA-Seq can help diagnose rare genetic diseases in children and adults who show early symptoms but have negative results from previous DNA tests called whole-exome sequencing WES. This project aims to set up and validate RNA-Seq techniques using healthy volunteers and patients with known genetic changes affecting RNA. The study focuses on identifying RNA changes in skin cells and comparing these to blood samples to better understand diseases that are hard to diagnose. Participants include healthy adults, patients with diagnosed genetic diseases affecting RNA, and undiagnosed patients suspected of having rare genetic conditions. Skin biopsies will be taken to culture fibroblasts, which are then analyzed using RNA-Seq to detect RNA level and splicing alterations. Blood samples will also be collected to study genetic and RNA changes. The study includes a discovery group with patients whose WES results were inconclusive, aiming to use RNA-Seq as an additional diagnostic tool. Participants will undergo skin biopsies and blood collection, and their samples will be stored in a biobank for analysis. Researchers will assess RNA changes in fibroblasts and compare RNA profiles from skin and blood. The main outcomes measure the setup and validation of RNA analysis methods and the detection of RNA alterations in patients. Participants will provide consent before enrollment, and their involvement includes sample collection and clinical information gathering. The study is expected to continue through June 2026.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of switching from anti-C5 antibody treatment to iptacopan in adults diagnosed with atypical hemolytic uremic syndrome aHUS. This Phase 3, multicenter, single-arm, open-label study aims to provide important data on how iptacopan works in patients who have already responded to anti-C5 antibody treatment. The study is sponsored by Novartis Pharmaceuticals and focuses on key measures related to aHUS symptoms and kidney function. Participants will receive iptacopan at a dose of 200 mg twice daily during the treatment periods. The study includes an initial screening period lasting up to 14 weeks, followed by a 12-month core treatment phase and then a 12-month extension treatment phase. This design allows researchers to observe the effects of iptacopan over a full two years after switching from previous therapy. Throughout the study, participants will undergo regular assessments including blood tests for platelet count, LDH, hemoglobin, kidney function markers such as serum creatinine and eGFR, and urine protein levels. Researchers will monitor for signs of thrombotic microangiopathy TMA and kidney disease progression, as well as track the need for dialysis. Safety and clinical responses will be evaluated at multiple time points to understand the treatment impact and participant well-being.
Actively Recruiting
Healthy Volunteer
Atypical Hemolytic Uremic Syndrome aHUS is a rare disease that causes destruction of red blood cells, low platelet counts, and blockage of small blood vessels, especially affecting the kidneys. Unlike the typical form caused by E. coli infection, aHUS may be linked to genetic mutations affecting the immune systems complement pathway or other genes like DGKE. This study aims to better understand the function of these rare genetic mutations in aHUS and explore potential personalized treatments. The study will include 110 children and adults diagnosed with aHUS who carry mutations in either the MCP or DGKE genes, along with 2 healthy volunteers as controls. Participants will provide blood and urine samples for laboratory analysis. Researchers will create patient-specific stem cells and turn them into endothelial cells to study their characteristics and viability. This process will help reveal differences between patients and healthy individuals. During the study, participants will undergo a single blood draw and urine test. Researchers will assess cell generation, differentiation, and function from the collected samples. The primary outcomes include the successful creation and detailed study of patient-derived cells. The study will monitor these laboratory measures once during the trial to better understand the disease mechanisms and identify possible drug targets. Participation length varies with no additional treatment given.
1-10 of 15
1